Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Publikováno v:
Leukemialymphoma. 59(6)
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT as
Publikováno v:
Leukemialymphoma. 59(2)
We evaluated the usefulness of interim 18F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Autor:
Young Seok Cho, Byung-Tae Kim, Yearn Seong Choe, Won Seog Kim, Seok Jin Kim, Kyung-Han Lee, Ah Young Lee, Seung Hwan Moon
Publikováno v:
Leukemialymphoma. 58(6)
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2–4 cycles. Predictors of progress
Autor:
Rika Kawasaki, Shigeki Motomura, Sachiya Takemura, Hirotaka Takasaki, Hideyuki Koharazawa, Hirohito Sone, Taisei Suzuki, Maki Hagihara, Kenji Motohashi, Naoto Tomita, Jun Taguchi, Chizuko Hashimoto, Rika Sakai, Etsuko Yamazaki, Jun Takizawa, Shin Fujisawa, Wataru Yamamoto, Takayoshi Tachibana, Katsumichi Fujimaki, Keisuke Kawamoto, Hiroyuki Fujita, Kazuho Miyashita
Publikováno v:
Leukemialymphoma. 57(12)
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclo
Autor:
Ja Young Seo, Kyung-Hee Kim, Jae Hoon Lee, Hyeongrae Cho, Jinny Park, Kayeong Chun, Pil Whan Park, Jihoon Jeong, Junshik Hong, Jeong Yeal Ahn
Publikováno v:
Leukemialymphoma. 58(2)
The prognostic role of detecting clonal immunoglobulin gene rearrangement (IgR) from bone marrow (BM) aspirates was evaluated by BIOMED-2 PCR in 97 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-CHOP immunochemotherapy. Si
Autor:
Bingshu E. Chen, John Kuruvilla, Kang Howson-Jan, Ralph M. Meyer, C. Tom Kouroukis, Tara Baetz, Marina S. Djurfeldt, Annette E. Hay, Rena Buckstein, Lois E. Shepherd, Stephen Couban, Massimo Federico, Michael Crump, David Szwajcer
Publikováno v:
Leukemialymphoma. 58(1)
The impact of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant (ASCT) was evaluated in a retrospective subgroup analysis of NCIC CTG LY.12. Among 414 patients who relapsed following R-CHOP, 96 received salvag
Autor:
Wen Zheng, Guiqiang Wang, Xiao Pei Wang, Yu Qin Song, Chen Zhang, Weiping Liu, Ling Yan Ping, Jun Zhu
Publikováno v:
Leukemialymphoma. 57(6)
The exact incidence and severity of hepatitis B virus (HBV) reactivation after the withdrawal of prophylactic antiviral therapy (delayed HBV reactivation) is unknown. We retrospectively analyzed 107 newly diagnosed diffuse large B cell lymphoma patie
Autor:
Lisa Durkin, Kelli M Clark Schneider, Angela M. B. Collie, Eric D. Hsi, Brian T. Hill, Christopher Lanigan, Peter M. Banks, Elena Manilich
Publikováno v:
Leukemialymphoma. 57(7)
Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by
Autor:
Sharon Wu, Erik Mittra, Susan M. Hiniker, Yasodha Natkunam, Richard T. Hoppe, Ranjana H. Advani, Michael S. Binkley
Publikováno v:
Leukemialymphoma. 57(3)
As the optimal treatment for primary mediastinal large B-cell lymphoma (PMBCL) remains undefined, we evaluated outcomes of patients treated with standard and dose-intense rituximab-chemotherapy (R-CT) with and without radiotherapy (RT). We retrospect
Autor:
Tzu-Chuan Huang, Chieh-Sheng Lu, Ming-Shen Dai, Yeu-Chin Chen, Ching-Liang Ho, Ping-Ying Chang, Yi-Ying Wu, Jia-Hong Chen
Publikováno v:
Leukemialymphoma. 56(7)
The National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI) is an enhanced prognostic tool that has identified some specific extranodal sites as a poor prognostic factor. We retrospectively analyzed 148 Taiwanese patients wi